gdc

Immunotherapy

The Immunotherapy Surge
Issue IntroductionsImmunotherapy
In this special issue focused on immunotherapy, we take a deep dive into this exciting type of treatment, highlighting the role of genetic testing and new developments in lung, skin, and bladder cancer in improving patient outcomes.
Molecular Profiling and Immunotherapy Offered Me New Hope After Stage IV Lung Cancer Diagnosis
ImmunotherapyLung CancerPatient StoriesGenomic Testing
Christie Bevington shares her story of how immunotherapy was the only treatment that helped stop her cancer progression and relieve her back pain caused by lung cancer.
Molecular Profiling Is Making Cancer Treatment Personal
ImmunotherapyMolecular TestingGenomic Testing
Tim Dorius, MD, explains the role of molecular profiling in relation to immunotherapy, and how oncologists can now look at the genetic makeup of a tumor to identify specific mutations or other biomarkers.
Hope Against All Odds: My Journey with Immunotherapy for Advanced Bladder Cancer
Bladder CancerImmunotherapyPatient Stories
Michael Morigi shares his very positive experience with immunotherapy in the treatment of his stage III bladder cancer.
Immunotherapy a Safe Option in Immunocompromised Patients with Advanced Skin Cancer
ImmunotherapySkin Cancer
Immunotherapy is showing good results in patients with advanced skin cancer, one of the most common types of cancer diagnosed in the United States.
Immunotherapy Brings New Hope for Patients with Non–Small-Cell Lung Cancer and PD-1/PD-L1 Biomarker
BiomarkersImmunotherapyLung Cancer
Two experts discuss the advances made in lung cancer with the introduction of new immunotherapies, which have extended life for patients, and why testing for biomarkers is crucial.
Jemperli First Immunotherapy FDA Approved for Endometrial Cancer with dMMR Biomarker
Endometrial CancerFDA Approvals, News & UpdatesImmunotherapy
In April 2021, the FDA approved Jemperli (dostarlimab-gxly) for patients with recurrent or advanced endometrial cancer and the biomarker mismatch repair-deficient. This is the first immunotherapy approved for patients with this type of cancer.
Opdivo First Immunotherapy Approved for First-Line Therapy of Gastric Cancers
FDA Approvals, News & UpdatesGastric CancerImmunotherapy
In April 2021, the FDA approved Opdivo (nivolumab), for use with chemotherapy, as first-line treatment for patients with advanced or metastatic gastric cancer, including gastroesophageal junction cancer and esophageal adenocarcinoma.
Keytruda Another Immunotherapy Approved for First-Line Treatment of Advanced Gastric Cancer
FDA Approvals, News & UpdatesGastric CancerImmunotherapy
In May 2021, the FDA approved Keytruda (pembrolizumab), plus Herceptin and chemotherapy, for first-line treatment of locally advanced unresectable or metastatic, HER2-positive gastric or gastroesophageal junction adenocarcinoma. Keytruda is the second immunotherapy approved for gastric cancer.
Is It Breast or Skin Cancer? How a Misdiagnosis Shaped My Cancer Journey
ImmunotherapyPatient StoriesSkin Cancer
Chris Andersen learned the value of trusting one’s instincts and asking for a second opinion after receiving a misdiagnosis of breast cancer that was later diagnosed as metastatic skin cancer and she was told she had 1 to 2 years to live. Thanks to a new treatment for skin cancer, she now has no signs of cancer.
Page 1 of 7
Results 1 - 10 of 65

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest